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Background: For colorectal liver metastases (CRLM) that are not amenable to surgery or 
thermal ablation, irreversible electroporation (IRE) is a novel local treatment modality and 
additional option. 
Methods: This study is a retrospective long-term follow-up of patients with CRLM who 
underwent IRE as salvage treatment.
Results: Of the 24 included patients, 18 (75.0%) were male, and the median age was 57 (range: 
28–75) years. The mean time elapsed from diagnosis to IRE was 37.9±37.3 months. Mean overall 
survival was 26.5 months after IRE (range: 2.5–69.2 months) and 58.1 months after diagnosis 
(range: 14.8–180.1 months). One-, three-, and five-year survival rates after initial diagnosis 
were 100.0%, 79.2%, and 41.2%; after IRE, the respective survival rates were 79.1%, 25.0%, 
and 8.3%. There were no statistically significant differences detected in survival after IRE with 
respect to gender, age, T- or N-stage at the time of diagnosis, size of metastases subject to IRE, 
number of hepatic lesions, or time elapsed between IRE and diagnosis. 
Conclusion: For nonresectable CRLM, long-term survival data emphasize the value of IRE as 
a new minimally invasive local therapeutic approach in multimodal palliative treatment, which 
is currently limited to systemic or regional therapies in this setting.
Keywords: liver metastases, survival, colorectal cancer, irreversible electroporation, long-term, 
salvage treatment, CRLM
Introduction
Colorectal cancer is the third most commonly diagnosed cancer in males and the second in 
females, with an estimated 1.4 million new cases and 693,000 deaths in 2012. The highest 
incidence rates are found in Australia, New Zealand, Europe, and Northern America.1 
While incidence rates are rising, mortality rates in colorectal cancer are decreasing, most 
likely due to increased screening, reduced prevalence of risk factors, and improved treat-
ments for early stage disease.2,3 In spite of these advancements, up to 80% of patients 
with colorectal liver metastases (CRLM) present with advanced stage disease at the time 
of diagnosis that is not amenable to surgery.4–7 In a setting of metastatic liver disease, 
minimally invasive therapies, such as irreversible electroporation (IRE),8,9 microwave 
ablation (MWA), radiofrequency ablation (RFA), or selective internal radiation therapy, 
are possible adjunct treatment options that can be performed after systemic or regional 
chemo- and immunotherapy.4 For patients with inoperable CRLM not suitable for ther-
mal ablation techniques, IRE is a novel local treatment option in addition to chemo- and 
immunotherapies.10,11 IRE is a nonthermal ablation procedure still under early clinical 
investigation.12 In contrast to techniques using thermal ablation, the electrical field in 
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IRE initially causes apoptosis instead of necrosis. Ultra-short 
high-voltage currents cause lethal pores in the cell membrane 
of tumor tissue, resulting in breakdown of the transmembrane 
potential13 via creation of nanopores in the cell membrane. 
With subsequent influx and efflux of ions through the lipid 
bilayer, apoptosis, rather than necrosis, is induced, at least 
initially.14 This allows for ablation of metastases aligned with 
critical structures, such as vessels or adjacent organs. Data on 
patient survival after percutaneous IRE are scarce.9 Herein, we 
report the results of long-term follow-up of 24 patients with 
inoperable CRLM who underwent IRE.
Materials and methods
Twenty-four sequential patients with inoperable liver metas-
tases from colorectal cancer treated with IRE (NanoKnife®, 
Latham, NY, USA) before July 2015 were included in this 
retrospective long-term follow-up study. Initially, all cases 
were individually discussed in the interdisciplinary tumor 
board, and all physicians involved agreed on IRE treatment. 
Inclusion criteria were as follows: CRLM, age >18 years, 
informed consent, and ineligibility for thermal ablation or 
surgery. Exclusion criteria covered any contraindication for 
general anesthesia, cardiac pacemakers or ICD, vascular infil-
tration, CRLM with extrahepatic spread, preexisting cardiac 
conditions such as arrhythmias or significant heart failure, 
and severe coagulopathies. The University of Regensburg 
Institutional Review Board waived approval for this study 
due to the retrospective and fully anonymized character. All 
patient data were kept strictly confidential, and all require-
ments of the Declaration of Helsinki were fulfilled. In accor-
dance with international, national, and local requirements, all 
patients provided written consent prior to IRE treatment.15,16 
All IRE procedures were performed under general anesthesia 
and as described previously.17 Follow-up imaging (MRI of the 
liver using a liver-specific contrast agent [Gd-EOB-DTPA]) 
was acquired 6 weeks post-IRE, quarterly for 2 years, and 
semi-annually thereafter.
Kaplan–Meier survival curves were calculated and plot-
ted using GraphPad Prism version 5.00a for Mac (GraphPad 
Software, San Diego, CA, USA). Log-rank statistics were 
calculated to identify factors of prognostic value for survival 
after either diagnosis or first IRE. Investigated variables 
included TNM tumor (T)/lymph node (N)/distant metastases 
(M) characteristics on diagnosis, gender, short axis diameter 
of IRE-treated lesions, and number of hepatic metastases. 
Age (young/old) and time of IRE (early/late) were grouped 
by the median cutoff. Survival was defined as either the time 
from diagnosis or the time from first IRE to death from any 
cause. Patients alive at the date last known were censored.
A value of P<0.05 for alpha was considered a statistically 
significant difference. For anonymized retrospective analyses, 
approval from the institutional ethics committee was waived.
Results
We included 24 patients with inoperable CRLM and IRE in 
our long-term follow-up study. Eighteen (75.0%) were male, 
and the median age was 57 years, with a range of 28–75 years. 
Table 1 contains additional baseline characteristics.
At the time of diagnosis, 70.8% (n=17) of patients 
had stage T3 or T4 tumors, 66.7% (n=16) had lymph node 
metastases (N1 or N2), and 87.5% (n=21) had metastatic 
disease. Further baseline characteristics of the tumors are 
shown in Table 2. The mean time elapsed from diagnosis 
to IRE was 37.9±37.3 months. Complete ablation was 
achieved in 16 (66.7%) of 24 patients after the first IRE. 
With reintervention, complete ablation was achieved in 23 
(95.8%) of 24 patients.
Table 1 Baseline patient characteristics
Characteristics
Female sex, n (%) 6 (25.0)
age at Dx (years)
Median 57
Range 28–75
age at iRe (years)
Median 58.5
Range 31–80
Time from Dx to iRe (months ± sD) 37.9±37.3
Abbreviations: Dx, diagnosis; iRe, irreversible electroporation.
Table 2 Baseline tumor characteristics
Characteristics
TnM staginga, n (%)
T1 1 (4.2)
T2 5 (20.8)
T3 13 (54.2)
T4 4 (16.7)
n0 7 (29.2)
n1 10 (41.7)
n2 6 (25.0)
M0 2 (8.3)
M1 21 (87.5)
location, n (%)
Colon ascendens 4 (16.7)b
Colon transversum 2 (8.3)
Colon descendens 0 (0)
Colon sigmoideum 5 (20.8)b
Rectum 15 (62.5)
hepatic metastases, n ± sD, range, median 2.0±1.9, 1–9, 2
short axis diameter of iRe-treated hepatic 
metastases, cm ± sD, range, median
2.3±1.1, 0.5–4.5, 2
Note: aMissing data for one patient; bone case of simultaneous colon ascendens and 
colon sigmoideum.
Abbreviation: iRe, irreversible electroporation.
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There were no statistically significant differences between 
young vs old patients (median split; χ2=1.335; P=0.25; 
median: 23.9 vs 26.5 months; Figure 2B), female vs male 
patients (χ2=1.302; P=0.25; median: 21.0 vs 26.5 months; 
Figure 2A), early vs late IRE (median split; χ2=0.3908; 
P=0.53; median: 26.1 vs 26.5 months; Figure 3B), one vs two 
or more hepatic metastases (χ2=1.435; P=0.23; median: 24.6 
vs 29.0 months; Figure 1C), small vs large (≥2 cm) metastases 
subject to IRE treatment (χ2=2.717; P=0.10; median: 32.0 vs 
21.1 months; Figure 3A), initial tumor stage (T1/2 vs T3/4; 
χ2=0.7287, P=0.39; median: 34.5 vs 26.5 months; Figure 1A), 
or initial lymph node metastases (N0 vs N1 vs N2; χ2=0.8407, 
P=0.66; median: 16.6 vs 29.0 vs 26.7 months; Figure 1B).
Overall survival was 26.5 months after IRE (range: 2.5–69.2 
months) and 58.1 months after diagnosis (range: 14.8–180.1 
months). One-, three-, and five-year survival rates after IRE 
were 79.1%, 25.0%, and 8.3%; the respective survival rates after 
initial diagnosis were 100.0%, 79.2%, and 41.2% (Table 3).
Figure 3 Kaplan–Meier survival curves based on iRe treatment characteristics. 
Notes: Comparison of size of CRLM subjected to IRE and time of IRE after diagnosis, no statistically significant difference was found. (A) size of the treated metastasis 
(smaller vs ≥2 cm). (B) early (e) or late (l) iRe, split by the median.
Abbreviations: CRlM, colorectal liver metastases; iRe, irreversible electroporation.
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Figure 1 Kaplan–Meier survival curves based on tumor characteristics.
Notes: There were no statistically significant differences comparing T- and N-stage at the time of diagnosis or number of CRLM at the time of IRE. (A) T1/2 and T3/4. (B) 
n0, n1, and n2. (C) One or more than one (2+) hepatic metastases.
Abbreviations: CRlM, colorectal liver metastases; iRe, irreversible electroporation.
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Figure 2 Kaplan–Meier survival curves based on patient characteristics.
Notes: No statistically significant difference was detected between gender and age. (A) Female (F) and male (M). (B) Young (Y) and old (O) patients, split by the median.
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Discussion
Percutaneous ablation techniques have become a treatment 
option with several indications, including inoperable liver 
malignancies. While thermal ablation techniques, such as 
RFA or MWA, are limited by the so-called heat sink effect, 
nonthermal ablation with IRE is advantageous in the treat-
ment of liver lesions adjacent to great vessels. IRE does 
not cause damage to intact adjacent structures, such as bile 
ducts,18 vessels, gall bladder, diaphragm, or heart, reducing 
the risk of complications. With advanced stage disease, 
patients in our cohort received IRE as a last treatment option. 
Since it is known that incomplete ablation of liver lesions 
causes decreased survival19 due to local recurrence20–22 
and simultaneous tumor spread,23 IRE is very valuable for 
inoperable CRLM.24 In this palliative setting, our study was 
solely focused on survival, not covering local recurrence as 
primary or secondary end points. Ruers et al were the first to 
show that aggressive local treatment of CRLM, in addition 
to chemotherapy, prolongs overall survival.25
For hepatic metastases, IRE is the very last nonsystemic 
treatment option. It can even be suitable for lesions not ame-
nable to surgery or thermal ablation. For CRLM, we observed 
a median survival of 26.6 months after the first IRE, which 
is markedly longer than that for the usual systemic treatment 
approaches alone. After completion of chemotherapy with 
fluorouracil and oxaliplatin, a median survival of 19.5 months 
has been reported,26 and for irinotecan, fluorouracil, and leu-
covorin, a median survival of 14.8 months was observed.27 
Following chemotherapy with irinotecan and fluoropyrimidine, 
additional treatment with bevacizumab in combination with 
oxaliplatin, fluorouracil, and leucovorin conveyed an additional 
median survival of 12.9 months.28 From the time of diagnosis, 
our cohort reached a median survival of 58.1 months. Song 
et al compared MWA and resection of operable CRLM, not 
giving details on survival; however, an overall survival of little 
>60 months for MWA can be estimated.29
In our cohort, all patients were pretreated, and IRE was 
an additional therapeutic modality implemented in case 
with no alternative. The cases included in this cohort were 
not only inoperable but were also not amenable to thermal 
ablation. Thus, comparable data concerning survival benefits 
are very limited. van Iersel et al report a median survival of 
25.0 months for isolated hepatic perfusion and 21.7 months 
for capecitabine, irinotecan, and oxaliplatin in isolated non-
resectable CRLM.30 Solbiati et al report a 5-year survival of 
47.8% for RFA added to systemic chemotherapy in patients 
not eligible for surgery or who refused surgery, compared 
to 41.2% in our cohort,31 comprised of patients who under-
went various other therapies before IRE. For RFA as salvage 
therapy after hepatectomy, a 3-year survival of 41% was 
reported, compared to 25.0% (after IRE) and 79.2% (after 
diagnosis) in our cohort.32
Due to the small cohort and retrospective study design, 
it is difficult to draw broad conclusions concerning the 
value of IRE in the treatment of secondary, inoperable liver 
malignancies. With a median survival longer than standard 
chemotherapy regimens, IRE should be regarded as the 
option-of-choice for patients with inoperable liver metas-
tases who are not suitable for thermal ablation procedures. 
Further prospective randomized studies with a larger number 
of patients are needed to evaluate the value of IRE in the 
setting of CRLM. Moreover, detailed analysis of additional 
biomarkers, such as KRAS,33 as prognostic indicators is 
needed.34,35 In light of IRE being without an alternative in 
selected cases,17,36–38 a median survival of 26.6 months after 
first IRE is a promising result. Thus, we conclude that IRE 
is a valuable therapy for patients with CRLM not amenable 
to surgery or thermal ablation.
Disclosure
The authors report no conflicts of interest in this work.
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